Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for China Pharma Holdings (CPHI) over the last 16 years, with Q3 2025 value amounting to -$122214.0.

  • China Pharma Holdings' Cash from Financing Activities fell 188597.11% to -$122214.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$214633.0, marking a year-over-year decrease of 52143.57%. This contributed to the annual value of $27353.0 for FY2024, which is 6260.44% down from last year.
  • Per China Pharma Holdings' latest filing, its Cash from Financing Activities stood at -$122214.0 for Q3 2025, which was down 188597.11% from -$29188.0 recorded in Q2 2025.
  • China Pharma Holdings' Cash from Financing Activities' 5-year high stood at $4.6 million during Q4 2021, with a 5-year trough of -$850555.0 in Q2 2022.
  • In the last 5 years, China Pharma Holdings' Cash from Financing Activities had a median value of $934.0 in 2023 and averaged $142462.8.
  • In the last 5 years, China Pharma Holdings' Cash from Financing Activities skyrocketed by 4592852.89% in 2021 and then tumbled by 188597.11% in 2025.
  • Quarter analysis of 5 years shows China Pharma Holdings' Cash from Financing Activities stood at $4.6 million in 2021, then plummeted by 114.55% to -$672063.0 in 2022, then skyrocketed by 104.52% to $30378.0 in 2023, then plummeted by 77.61% to $6802.0 in 2024, then tumbled by 1896.74% to -$122214.0 in 2025.
  • Its last three reported values are -$122214.0 in Q3 2025, -$29188.0 for Q2 2025, and -$70033.0 during Q1 2025.